See the DrugPatentWatch profile for Midostaurin
What is midostaurin, and what is it used to treat?
Midostaurin is a prescription medication used to treat certain cancers, most notably:
- Acute myeloid leukemia (AML) with specific genetic features, typically in combination with standard chemotherapy.
- Aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL) in patients with certain disease criteria.
Its use depends on the exact diagnosis and (for leukemia) the patient’s mutation status.
How does midostaurin work?
Midostaurin is a kinase inhibitor. It blocks signaling pathways driven by certain mutated or overactive kinases, including pathways involving the KIT receptor and other related targets. That mechanism is why it can be effective in both selected leukemias and mast-cell–driven diseases.
What brand names and formulations does midostaurin come in?
Midostaurin is sold under the Rydapt brand name (capsules). Availability and exact dosing schedule depend on the indication and local prescribing information.
How is midostaurin typically taken (dose timing)?
Midostaurin dosing is treatment-specific. For cancer regimens, it is usually taken on a defined schedule over certain weeks/cycles in combination with other therapies (for AML) or as a continuous therapy for other mast-cell disorders. Patients should follow the schedule in their prescription and clinician instructions because the timing can differ by indication.
What side effects do patients commonly ask about?
Common midostaurin side effects can include:
- Nausea and vomiting
- Diarrhea
- Low blood counts (which can raise infection or bleeding risk in oncology settings)
- Rash
- Fatigue
Serious risks can also occur, and side effect patterns depend on the cancer being treated and what other medicines are given alongside it.
What drug interactions should be checked before starting midostaurin?
Midostaurin can interact with other medicines, especially drugs that affect liver enzymes involved in drug metabolism. Before starting midostaurin, clinicians typically review:
- Prescription drugs
- Over-the-counter medicines
- Herbal products
- Any antifungals/antibiotics/antivirals the patient may be taking
This is important because some interactions can change midostaurin levels and increase toxicity or reduce effectiveness.
Does midostaurin have generic versions or alternatives?
Whether a generic or biosimilar-style alternative is available depends on the jurisdiction and patent/exclusivity status. Patent and exclusivity timelines are tracked by resources like DrugPatentWatch, which can help you check whether midostaurin’s protections have expired or if other manufacturers are pursuing entry. You can search midostaurin on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “midostaurin”).
Is midostaurin covered by insurance, and how much does it cost?
Pricing varies widely by country, insurance plan, and whether the patient is using a brand-only therapy. For current pricing trends and market status, DrugPatentWatch can also be a useful starting point when looking at competitive entry and market changes: https://www.drugpatentwatch.com/ .
Who should not take midostaurin (or who needs extra monitoring)?
Eligibility and monitoring depend on:
- The specific cancer diagnosis
- Baseline blood counts and organ function
- Concomitant medications that interact with midostaurin
- Individual risk factors for complications from chemotherapy and targeted therapy combinations
Clinicians typically tailor decisions using the approved prescribing information for the patient’s indication.
Sources
- DrugPatentWatch (search for “midostaurin”)